Home / Medical Devices / Endoscopic Ultrasound (EUS) Needles Market By Product (Aspiration Needles (EUS-FNA), Biopsy Needles (EUS-FNB)), By Disease Type (Gastrointestinal (GI) Diseases, Lung Diseases, Liver & Hepatobiliary Diseases, Pancreatic Diseases, Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Endoscopic Ultrasound (EUS) Needles Market By Product (Aspiration Needles (EUS-FNA), Biopsy Needles (EUS-FNB)), By Disease Type (Gastrointestinal (GI) Diseases, Lung Diseases, Liver & Hepatobiliary Diseases, Pancreatic Diseases, Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Published: Jul 2018 | Report Code: 59227-07-18

Summary
Table of Content
List of Figures
List of Tables

Endoscopic Ultrasound (EUS) Needles Market to Exhibit Lucrative Growth during the Forecast Period

The global endoscopic ultrasound needles market accounted for a value of US$ 289.3 Mn in 2017 and expected to attain US$ 440.4 Mn by 2026. Growing geriatric population coupled with rising prevalence of diseases such as gastrointestinal, lung, liver & hepatobiliary, and pancreatic, worldwide are majorly driving the market growth. Additionally, technological advances in endoscopic ultrasound needles and increasing patient preference for minimally invasive surgeries are anticipated to display significant future outlook over the forecast period from 2018 to 2026. According to the World Health Organization (WHO), the elderly population will surge from 841.0 Mn in 2013 to 962.3 million in 2017 to over 2.0 Bn by 2050 across the globe. According to the United Nations (an intergovernmental organization), by 2050, elder population may account for 35.0% of the population in Europe, 28.0% in North America, 25.0% in Latin America & the Caribbean, 24.0% in Asia, 23.0% in Oceania, and 9.0% in Africa. The older population is more prone to develop gastrointestinal (GI) diseases, lung diseases, liver & hepatobiliary diseases, pancreatic diseases among others. As per the data published by World Cancer Research Fund International, worldwide there were 952,000 new cases diagnosed in 2012. In 2015, the WHO reported that about 754,000 deaths occurred due to stomach cancer, lung cancer — 1.69 million deaths, and liver cancer — 788,000 deaths. According to the American Lung Association, in 2018, around 415,000 Americans were diagnosed with lung cancer. In 2016, about 224,390 new cases of lung cancer were diagnosed in the country. On the contrary, risk of complications associated with EUS such as infection, bleeding, pancreatitis, tearing of the intestinal wall or throat are anticipated to limit the use of EUS during the forecast period.

Market Synopsis

The Aspiration Needles (EUS-FNA) Segment is expected to Register Comparatively Higher Growth over the Forecast Period

Aspiration needles are intended for diagnosis & staging of various lesions located in and around the gastrointestinal tract and of adjacent organs. The EUS-FNA is performed usually at several endoscopic centers and it has a significant impact on the therapeutic management of patients. Rising adoption of aspiration needles for the treatment of gastrointestinal diseases, lung diseases, liver & hepatobiliary diseases, and pancreatic diseases among others expected to continue the dominance of the aspiration needles segment during the forecast period.